According to filings with the U.S. Securities and Exchange Commission, InduPro has raised $77 Million in new Series B funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: The Column Group, Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, Eli Lilly and Company

About InduPro
InduPro is a biotechnology company focused on developing next generation therapeutics by precisely manipulating the spatial relationships of proteins on the cell surface to create new signaling pathways and logic gates. Using proprietary proximity based and cell surface platform technologies, InduPro brings proteins closer together and defines surface protein neighborhoods, enabling the identification of novel drug targets and innovative target pairings, including multispecific biologics such as bispecific antibodies, antibodydrug conjugates, and T cell engagers. Its approach is applied across oncology and autoimmune diseases, where this proximity biology platform supports a differentiated pipeline with both first and best in class potential, including candidates moving from discovery and preclinical work into clinical development. The company emphasizes integrating advanced AI/ML with experimental biology to map and exploit inherent and induced protein proximity, positioning itself as a leader in proximity based protein therapeutics. InduPro operates from Seattle and Boston, assembling a multidisciplinary team from pharma, academia, and biotech, and presents itself as committed to delivering life changing therapies by turning complex cell surface insights into transformative medicines for patients.

To learn more, visit https://www.induprotx.com/
Linkedin: https://www.linkedin.com/company/induprotx

Contact:
Prakash Raman, Chief Executive Officer
https://www.linkedin.com/in/prakash-raman-49ab713

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.